Squalene nanoemulsion reinforces mucosal and immunological fingerprints following intravaginal delivery - 03/09/21
pages | 7 |
Iconographies | 6 |
Vidéos | 0 |
Autres | 0 |
Abstract |
This study describes the assessment of mucosal adjuvant activity of a squalene-based nanoemulsion (SQ@NE) following intravaginal delivery in mice. After immunization, a high level of recruitment of CD11b/c+ granulocytes and F4/80+ macrophages was observed in the vaginal mucosal tissues of the mice immunized with a model protein ovalbumin (OVA) formulated with SQ@NE, and then downstream regulated the expression of MHC II and costimulatory molecules CD40 and CD86 on CD11c+ cells harvested from the associated draining lymph node. With respect to cytotoxic T lymphocyte immunity, the mice immunized with SQ@NE-formulated OVA elicited a high population of OVA-specific CD8+ cells in the spleen and increased the secretion of IFN-γ, IL-2 and IL-17 from OVA-restimulated splenocytes compared with those immunized with OVA alone. By studying in vivo fluorescence imaging and B-cell immunoassays, we discovered how SQ@NE prolongs the retention of antigen depots at the mucosal membrane of the immune inductive site and allows them to properly drive the production of antibodies. The data demonstrated that SQ@NE prolonged fluorescence-labeled OVA retention at the genital tract and augmented the production of OVA-specific IgG in sera and IgA in vaginal washes. These results indicate that SQ@NE is a promising vaginal adjuvant for the induction of both mucosal and systemic immune responses, a feature that provides implications for the development of a mucosal vaccine against genital infections and sexually transmitted diseases.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Mucosal/immunological fingerprints of squalene nanoemulsion (SQ@NE) were assessed. |
• | SQ@NE tones up the numbers of APCs at vaginal MALT and associated dLNs. |
• | SQ@NE rephrases the activation of CD8+ CTLs and helper T cells. |
• | SQ@NE prolongs protein antigen delivery in the vagina and drives humoral immunity. |
Keywords : Mucosal adjuvant, Nanoemulsion, Squalene, Vaccine, Vaginal delivery
Plan
Vol 141
Article 111799- septembre 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?